Efficacy and Thrombotic Risk of Thrombopoietin Receptor Agonists for Immune Thrombocytopenia Secondary to Systemic Lupus and Antiphospholipid Syndrome: French Experience With 80 Patients.

ABSTRACT: Only few data are available regarding the efficacy and safety of thrombopoietin receptor agonists (TPO-RAs) for treating systemic lupus erythematosus (SLE) and/or antiphospholipid syndrome (APS)-associated immune thrombocytopenia (ITP). We retrospectively assessed the efficacy and safety of TPO-RAs in 80 adults with ITP in three subgroups: (1) 37 patients with definite or incomplete SLE and no antiphospholipid antibodies (APAs), (2) 27 patients with definite or incomplete SLE associated with APAs and no history of arterial or venous thrombotic events (TEs) and (3) 16 patients with APS. In total, 39 (48.8%) patients received eltrombopag, 14 (17.5%) romiplostim and 27 (33.8%) both TPO-RAs sequentially. The overall response of ITP was 78.8%. In total, 17 (21.3%) patients had 21 TEs (7 venous

SUBMITTER: Marques C 

PROVIDER: S-EPMC12516675 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature